Oportuzumab monatox
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | EpCAM |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
945228-48-8  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C3072H4723N877O952S12 |
| Molar mass | 69.6 kg/mol |
 (what is this?) (verify) | |
Oportuzumab monatox (proposed INN), trade name "Vicinium" is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio <http://www.viventia.com, a Canadian company with laboratories in Winnipeg, Canada and headquarters in Philadelphia, Pennsylvania, USA. Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).[1]
Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer.[2] In these studies, treatment was associated with clinical benefit.
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald and N. Glover. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 4580